Affiliation:
1. Takeda Pharmaceuticals U.S.A.; Inc.; Deerfield IL USA
Funder
Takeda Pharmaceutical Company
Subject
Pharmacology (medical),Pharmaceutical Science
Reference24 articles.
1. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder;Mork;J Pharmacol Exp Ther,2012
2. In vitro and in vivo effects for the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets;Westrich;Int J Psychiatry Clin Pract,2012
3. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder;Bang-Andersen;J Med Chem,2011
4. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder;Alvarez;Int J Neuropsychopharmacol,2012
5. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder;Henigsberg;J Clin Psychiatry,2012
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献